<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of giant cell arteritis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of giant cell arteritis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of giant cell arteritis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carlo Salvarani, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Francesco Muratore, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan Trobe, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth J Warrington, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 17, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Giant cell arteritis (GCA, also known as Horton disease, cranial arteritis, and temporal arteritis) is the most common systemic vasculitis in North America and Europe [<a href="#rid1">1,2</a>]. GCA affects only older adults, with a peak incidence between ages 70 and 79 [<a href="#rid3">3</a>]. Many of the clinical features of the disease result from vascular inflammation of the small extracranial branches of the carotid arteries. One of the most concerning potential complications of GCA is that of sight loss, which serves as the rationale for prompt initiation of glucocorticoids as soon as the diagnosis is suspected. The disease can be generalized, however, and involve the aorta, leading to aneurysms of the thoracic aorta, and may cause stenoses in the large arteries, resulting in ischemic symptoms of the extremities.</p><p>The treatment and prognosis of GCA are reviewed here. The clinical manifestations and diagnosis of this disorder are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8225.html" rel="external">"Clinical manifestations of giant cell arteritis"</a> and  <a class="medical medical_review" href="/z/d/html/8242.html" rel="external">"Diagnosis of giant cell arteritis"</a>.)</p><p class="headingAnchor" id="H2401399313"><span class="h1">INITIAL MANAGEMENT</span></p><p class="headingAnchor" id="H1408267668"><span class="h2">No visual loss at diagnosis</span></p><p class="headingAnchor" id="H5"><span class="h3">Glucocorticoids</span><span class="headingEndMark"> — </span>For all patients with giant cell arteritis (GCA), we recommend initial treatment with high-dose glucocorticoids rather than a moderate dose of glucocorticoids. The specific dose and route of administration of glucocorticoids for newly diagnosed GCA varies depending on whether the patient presents with or without threatened or established visual loss at diagnosis. (See <a class="local">'Threatened or established visual loss at diagnosis'</a> below.)</p><p>For patients without signs of ischemic organ damage (eg, visual loss), we initiate glucocorticoid therapy with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 40 to 60 mg/day (or equivalent) administered in a single daily dose, with the goal of relieving symptoms and preventing visual loss. In selected cases in which reversible symptoms persist or worsen, the dose can be increased until symptomatic control is achieved (up to a maximum of prednisone 80 mg or equivalent).</p><p>We do <strong>not</strong> use lower doses of glucocorticoids (ie, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> &lt;40 mg/day) as initial therapy in any patients with newly diagnosed GCA. In patients at high risk of developing glucocorticoid toxicity, we also use high doses of glucocorticoids and add a glucocorticoid-sparing agent. The approach to using a glucocorticoid-sparing agent and glucocorticoid tapering is discussed in detail below. (See <a class="local">'Glucocorticoid-sparing agent in selected patients'</a> below and <a class="local">'Glucocorticoid tapering'</a> below.)</p><p>Patients usually report dramatic improvements of many GCA-related symptoms (eg, headache, fever, malaise) within 24 to 48 hours of glucocorticoid administration. The diagnosis of GCA should be reevaluated in patients who are resistant to adequate glucocorticoid therapy, especially in situations where temporal artery biopsy and imaging studies have been negative. (See  <a class="medical medical_review" href="/z/d/html/8242.html" rel="external">"Diagnosis of giant cell arteritis", section on 'Diagnosis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Though never studied in a randomized trial, the role of glucocorticoids for the prevention of visual loss is supported by observational data and decades of clinical experience [<a href="#rid4">4-6</a>]. In a retrospective study of 245 patients with biopsy-proven GCA, all of whom were treated with glucocorticoids, permanent visual loss was found in 34 patients (14 percent) [<a href="#rid5">5</a>]. However, vision loss occurred in 32 of the 34 patients before the initiation of glucocorticoids. Of the two cases of de novo visual loss that developed after glucocorticoids were started, one occurred eight days into treatment, and the other occurred three years after glucocorticoids were first administered and one year after their discontinuation when the erythrocyte sedimentation rate (ESR) was normal and was therefore unlikely related to GCA. In another study of 144 patients with biopsy-proven GCA described in the ophthalmologic literature, none of the 53 patients with normal vision at presentation lost vision after initiation of glucocorticoids [<a href="#rid6">6</a>]. Of the 91 patients with sight loss at presentation, 9 experienced further visual loss after beginning glucocorticoids, all within 5 days of the start of treatment. Thus, if vision is intact at the time of the diagnosis of GCA, treatment with glucocorticoids appears to reduce the risk of sight loss to less than 1 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Data regarding</strong> <strong>initial dose</strong> – There are no clinical trials comparing different initial oral glucocorticoid doses for newly diagnosed GCA; however, clinical experience and observational data suggest that almost all patients with GCA respond symptomatically within 1 to 7 days to a 40 to 60 mg of oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (or equivalent) [<a href="#rid4">4,7-10</a>]. As an example, a population-based study with 120 patients with GCA found that all patients responded rapidly to a median initial dose of 60 mg of prednisone daily [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1">Our approach to the initial glucocorticoid dose is consistent with the European Alliance of Associations for Rheumatology (EULAR; formerly European League Against Rheumatism) guidelines, which recommend a fixed starting dose of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 40 to 60 mg daily (or equivalent) [<a href="#rid11">11</a>]. By contrast, the American College of Rheumatology (ACR) guidelines recommend a starting dose of 1 mg/kg of prednisone or equivalent, up to a maximum of 80 mg daily [<a href="#rid12">12,13</a>]. Our preference is based on the fact that the majority of clinical trials have used fixed starting doses of prednisone 60 mg daily, and that additional high-quality data on the optimal starting dose of glucocorticoids in GCA are lacking. We do not use starting doses of &lt;40 mg/day, as the use of such doses have not been systematically studied.</p><p></p><p class="bulletIndent1">There is insufficient evidence to justify the upfront use of intravenous pulse glucocorticoids in all patients with GCA, although they are recommended in patients with visual loss at presentation (see <a class="local">'Threatened or established visual loss at diagnosis'</a> below). A randomized trial with 164 patients with GCA (without ocular involvement at presentation) found no differences in the cumulative glucocorticoid doses or the number of GCA complications when comparing three different glucocorticoid protocols, two of which consisted of different pulse glucocorticoid regimens on a background of oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (240 mg intravenous pulse of <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> followed by 0.7 mg/kg/day oral prednisone or 240 mg intravenous pulse methylprednisolone followed by 0.5 mg/kg/day) and the other of which consisted of only oral prednisone (0.7 mg/kg/day) [<a href="#rid14">14</a>]. Another small randomized study of 27 patients without ocular involvement found that adding initial pulse glucocorticoid therapy resulted in a reduced total exposure to glucocorticoids and a lower relapse rate [<a href="#rid15">15</a>]. Neither of these randomized trials, however, was designed to assess the outcome of ocular complications.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No role for alternate-day dosing</strong> – Treatment of GCA requires daily glucocorticoid administration. The importance of daily dosing was demonstrated in the course of a study on the use of <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> for the management of GCA in which a rapid glucocorticoid taper to an alternate-day dose was associated with new sight loss in 8 of 98 patients [<a href="#rid16">16</a>]. In another study of regimens for glucocorticoid dosing, daily doses were more effective than alternate-day doses for symptomatic management [<a href="#rid17">17</a>].</p><p></p><p>The risks of high-dose and of chronic glucocorticoid therapy are well known and include cataracts, fractures, infections, hypertension, diabetes, osteoporosis, and osteonecrosis [<a href="#rid7">7</a>]. Other side effects of glucocorticoids include weight gain; hair loss; and capillary fragility, which can be especially problematic in older adults on antiplatelet or anticoagulant therapies. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p class="headingAnchor" id="H4159164883"><span class="h3">Glucocorticoid-sparing agent in selected patients</span></p><p class="headingAnchor" id="H988056691"><span class="h4">Indications and rationale</span><span class="headingEndMark"> — </span>For patients with newly diagnosed GCA with increased risk of glucocorticoid-related adverse effects, we suggest the addition of <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> to glucocorticoids. Patients who are at increased risk of developing glucocorticoid-related side effects or complications include those with osteoporosis, diabetes, hypertension, or glaucoma. We also add tocilizumab at first disease relapse, which is discussed further below. (See <a class="local">'Tocilizumab'</a> below and <a class="local">'Management'</a> below.)</p><p><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> may be used as an alternative glucocorticoid-sparing agent for patients who are unable to use <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> due to factors such as availability, cost, recurrent infections, or a history of gastrointestinal perforations or diverticulitis. (See <a class="local">'Methotrexate'</a> below.)</p><p>Our approach to the use of a glucocorticoid-sparing agent is consistent with the EULAR guidelines [<a href="#rid11">11</a>] but differs from those of the ACR [<a href="#rid12">12,13</a>], in which <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> use is recommended for all newly diagnosed patients with GCA. Despite the glucocorticoid-sparing effects of tocilizumab and its beneficial effects of remission rates, our caution with the use of tocilizumab is based on the lack of definitive data confirming the safety of long-term exposure of tocilizumab in an older adult population with multiple comorbidities. Furthermore, there are no definitive data showing that tocilizumab is able to reduce glucocorticoid-related side effects or definitively alter the inflammation in patients with large vessel disease. (See <a class="local">'Tocilizumab'</a> below.)</p><p class="headingAnchor" id="H179055212"><span class="h4">Tocilizumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">Tocilizumab</a> is administered as a 162 mg subcutaneous weekly injection or as a monthly intravenous infusion in combination with glucocorticoids. When tocilizumab is administered intravenously, we typically dose it at 8 mg/kg once every four weeks (with a maximum of 800 mg/infusion). The dose more commonly used in the United States is 6 mg/kg based on regulatory approval. Tocilizumab may be administered as monotherapy following discontinuation of glucocorticoids.</p><p>In patients who develop an adverse event (eg, cytopenias or abnormal liver function tests) with the standard initial dose, the <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> dose should be adjusted and injections can be administered every other week or the intravenous dose can be reduced to 4 mg/kg. The risks of tocilizumab include opportunistic infection, neutropenia, abnormal liver function tests, increased serum cholesterol, diverticulitis, and gastrointestinal perforation. Additional information regarding dose adjustments and adverse effects are described separately as well as in the Lexicomp drug information topic within UpToDate. (See  <a class="medical medical_review" href="/z/d/html/129345.html" rel="external">"Interleukin 6 inhibitors: Biology, principles of use, and adverse effects", section on 'Adverse effects'</a>.)</p><p>The optimal duration of therapy with <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> is unknown. We generally continue treatment for 12 to 18 months. If clinical remission is maintained, and glucocorticoids are successfully tapered off, we attempt complete discontinuation of tocilizumab. In some patients with relapsing disease who achieve sustained remission with tocilizumab, we try spacing out the tocilizumab injections to every other week (or reduce the dose of the intravenous infusion) for a period of 6 to 12 months before complete discontinuation.</p><p>A pragmatic concern with the use of <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> in the management of GCA pertains to its effects on the acute phase reactants. Interleukin (IL) 6 is a major driver of the acute phase response through its induction of hepatic synthesis of acute phase proteins (see  <a class="medical medical_review" href="/z/d/html/7483.html" rel="external">"Acute phase reactants"</a>). Blockade of IL-6 activity completely normalizes the ESR and C-reactive protein (CRP), with the result that the assessment of GCA in a patient on tocilizumab must rely on clinical evaluation and, in the case of large vessel involvement, periodic imaging studies. There continues to be an unfulfilled need for a reliable marker of active disease in GCA. (See <a class="local">'Routine monitoring of disease activity'</a> below and <a class="local">'Imaging surveillance for patients with large vessel involvement'</a> below.)</p><p>The beneficial effects of <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> as a glucocorticoid-sparing intervention have been demonstrated in two randomized trials [<a href="#rid18">18,19</a>]. In an industry-sponsored Giant Cell Arteritis Actemra (GiACTA) trial, 251 patients with newly diagnosed or relapsing GCA were randomly assigned to receive either weekly or every-other-week subcutaneous tocilizumab injections, combined with a 26-week <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> taper, or placebo combined with a prednisone taper over a period of either 26 or 52 weeks [<a href="#rid19">19</a>]. Patients with evidence of critical optic ischemia were not enrolled in the study. Sustained remission at 52 weeks occurred in 56 percent of the weekly tocilizumab group and in 53 percent of the every-other-week tocilizumab group, compared with 14 percent of the placebo group who tapered over 26 weeks and 18 percent of the placebo (prednisone-only) group who tapered over 52 weeks. When normalization of the CRP concentration was excluded from the definition, sustained remission at 52 weeks occurred in 59 percent of the weekly tocilizumab group and in 55 percent of the every-other-week tocilizumab group, compared with 20 percent of the placebo group, who tapered over 26 weeks, and 33 percent of the placebo (prednisone-only) group, who tapered over 52 weeks. The cumulative median prednisone dose over the 52-week period in each tocilizumab group was 1862 mg, as compared with 3296 mg in the placebo group on the 26-week taper and 3818 mg in the placebo group on the 52-week taper. Serious adverse events were more common in the placebo groups, most of which were related to infection. One patient in the group receiving tocilizumab every other week had an episode of anterior ischemic optic neuropathy (AION) that resolved with glucocorticoid treatment.</p><p>Information about long-term effects of <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> treatment on the disease course are limited [<a href="#rid18">18,19</a>]. In the two-year extension study of the GiACTA trial, after tocilizumab discontinuation, relapses were common, occurring in over half of patients enrolled [<a href="#rid20">20</a>]. Restarting tocilizumab (with or without glucocorticoids) was effective in restoring clinical remission in most patients. The glucocorticoid-sparing effect of tocilizumab demonstrated in the initial trial was maintained through year 3. Cumulative glucocorticoid doses over three years were significantly lower in patients originally randomized to tocilizumab compared with those originally randomized to placebo (median cumulative <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> dose 2647 mg for tocilizumab once a week, 3948 mg for tocilizumab every other week, 5277 mg for placebo with a 26-week prednisone taper, and 5323 mg for placebo with a 52-week prednisone taper). No new or unexpected safety findings were reported over the full three years of the study.</p><p>It remains to be seen whether <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> definitively resolves vessel inflammation and consequently prevents the long-term development of aortic aneurysm and supra-aortic vessels stenosis. In a case report, a patient with GCA in apparent remission on tocilizumab died of a postoperative myocardial infarction and was found on postmortem examination to have active arteritis of the aorta, subclavian arteries, and right superficial temporal artery [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H810686264"><span class="h4">Methotrexate</span><span class="headingEndMark"> — </span>When used, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> is typically initiated at a dose of 10 to 15 mg/week, with increases in dose every two to eight weeks of 5 mg/week up to 25 mg/week. We use the same regimen and approach to titration as that used in rheumatoid arthritis. (See  <a class="medical medical_review" href="/z/d/html/7507.html" rel="external">"Use of methotrexate in the treatment of rheumatoid arthritis", section on 'Dosing and administration'</a>.)</p><p>Limited data suggest that <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> is, at best, only moderately effective for reducing cumulative glucocorticoid dose and the rate of relapses [<a href="#rid22">22</a>]. Three randomized trials comparing methotrexate with placebo in patients with GCA treated with glucocorticoids reached divergent conclusions [<a href="#rid16">16,23,24</a>]. Of note, the doses of methotrexate used in the trials were low by contemporary standards, only 10 to 15 mg per week. A meta-analysis of the individual patient-level data of 161 patients from these three trials suggested that the add-on use of methotrexate resulted in a statistically significant reduction in the cumulative dose of glucocorticoids over the 48 weeks following randomization (cumulative dose reduction of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or equivalent of 842 mg), a decreased rate of first and second relapse, and a higher probability of achieving a glucocorticoid-free remission [<a href="#rid25">25</a>]. Adverse effects between the two treatment groups were similar. The superiority of methotrexate over placebo appeared only after 24 to 36 weeks.</p><p>There are no randomized trials comparing <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> with <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> in GCA. In an observational study on patients with new-onset, active, large vessel GCA starting treatment with either glucocorticoid monotherapy or combination with methotrexate or tocilizumab, all three treatment regimens controlled the clinical and biochemical signs of GCA and vascular inflammation evaluated by the positron emission tomography/computed tomography (PET/CT) [<a href="#rid26">26</a>]. Mean cumulative <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> doses, however, were higher with glucocorticoid monotherapy (5637 mg), intermediate with methotrexate (4478 mg), and significantly lower with tocilizumab (2984 mg).</p><p class="headingAnchor" id="H1965848205"><span class="h2">Threatened or established visual loss at diagnosis</span><span class="headingEndMark"> — </span>Patients who present with visual manifestations (amaurosis fugax or unilateral visual loss) or with cerebrovascular events (eg, stroke or transient ischemic attack) potentially attributed to GCA require a higher initial dose of glucocorticoids, which should be administered promptly. We use either 500 to 1000 mg/day of intravenous <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> daily for three days (followed by 40 to 60 mg/day of oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>) or 1 mg/kg/day of oral prednisone (if intravenous pulse cannot be rapidly initiated). While the association between diplopia and visual loss in patients with GCA has not been confirmed in all studies, we treat patients with GCA who present with diplopia with an initial course of intravenous glucocorticoids [<a href="#rid27">27</a>].</p><p>Though not validated in rigorous studies, this approach is used because of the crucial importance of preventing visual impairment due to GCA, which, once established, is rarely reversible [<a href="#rid15">15</a>]. The stark reality of such visual loss is that patients seldom recover useful vision in an affected eye [<a href="#rid28">28-30</a>]. In a retrospective review of 84 patients (114 eyes) with variable degrees of GCA-associated visual loss (due to AION in over 90 percent of patients), there were no differences in improvement in visual acuity when comparing patients who received intravenous glucocorticoids followed by oral therapy (41 patients) with patients who received only oral glucocorticoids (43 patients). Improvement in visual acuity was only observed in 4 percent of eyes (three patients treated with intravenous glucocorticoids and two with oral glucocorticoids), as judged by improvement in both visual acuity and central visual field (by kinetic perimetry and Amsler grid) [<a href="#rid28">28</a>]. Of note, improvement perceived by patients and noted on visual acuity tests may not reflect true recovery of retinal or optic nerve function but rather eccentric compensation for acquired, permanent visual deficits.</p><p>Limited data suggest that the timing of glucocorticoid therapy may be more important than the route of administration for the prevention of future severe ischemic events [<a href="#rid31">31</a>]. A retrospective multicenter study of 29 patients with GCA with permanent visual loss is the only study that used a cut-off interval time of 24 hours from diagnosis to treatment onset to define early treatment. Early treatment was the only significant predictor of improvement of visual acuity (odds ratio [OR] 17.7); the therapeutic regimen (intravenous pulse versus oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>) did not influence visual outcome [<a href="#rid32">32</a>].</p><p>Preexisting sight loss can progress, despite initiation of glucocorticoid therapy, in approximately 10 percent of patients, usually within the first week of treatment [<a href="#rid6">6</a>]. If untreated, the second eye is likely to become affected in up to 30 percent of patients, and more than half of these patients develop bilateral loss of vision within the first two weeks [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H1853685942"><span class="h2">Patients with large vessel involvement</span><span class="headingEndMark"> — </span>Large vessel GCA refers to involvement of the aorta and the great vessels, most commonly the subclavian arteries and distally to the axillary and brachial arteries. Patients with large vessel GCA are managed in a manner similar to those without large vessel involvement.</p><p>It remains uncertain whether large vessel involvement may require more protracted or intensive treatment. In one retrospective cohort study comparing 120 patients with large vessel GCA with 240 patients with cranial GCA, the patients with large vessel GCA had a higher cumulative glucocorticoid dose after one year of treatment, relapsed more frequently, and received more adjunctive immunosuppressant therapies [<a href="#rid34">34</a>]. Additional information regarding the clinical features of large vessel involvement is presented separately. (See  <a class="medical medical_review" href="/z/d/html/8225.html" rel="external">"Clinical manifestations of giant cell arteritis", section on 'Large vessel involvement'</a>.)</p><p>Additional management considerations for patients with large vessel include the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiplatelet therapy for selected patients</strong> – For patients who have critical or flow-limiting involvement of the cerebral or carotid arteries, we add low-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> to glucocorticoid and glucocorticoid-sparing therapy. If low-dose aspirin is used, a proton pump inhibitor should also be administered as aspirin, age, and high-dose glucocorticoids are all risk factors for gastrointestinal bleeding (see  <a class="medical medical_review" href="/z/d/html/35.html" rel="external">"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity", section on 'Proton pump inhibitors'</a>). The rationale for low-dose aspirin use in this setting is for prevention of ischemic events in patients with vascular narrowing resulting in decreased cerebral flow. Otherwise, there are limited data supporting the role of antiplatelet therapy for the prevention of ischemic events in patients with GCA [<a href="#rid35">35-39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vascular complications</strong> – For patients with vascular complications such as aortic aneurysms or stenosis resulting in limb or organ ischemia, management decisions regarding potential surgical intervention should involve collaboration of the vascular surgeon and the rheumatologist.</p><p></p><p class="bulletIndent1">For patients with GCA who require vascular surgical intervention and have clinical evidence of active disease, we typically use high-dose glucocorticoids in the periprocedural period. Clinical studies that would inform the management of complications such as limb ischemia or aortic aneurysms in GCA are lacking, and the approach to management is largely based on clinical experience and extrapolated from experience with Takayasu arteritis.</p><p></p><p class="bulletIndent1">Additional considerations regarding specific vascular complications include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ischemic limb symptoms</strong> – Most ischemic limb symptoms from stenosis improve or stabilize with medical management in GCA, and revascularization of arteries to the extremities (eg, angioplasty, stent placement, or bypass surgery) is seldom required. Vasculitic narrowing of large arteries, such as the subclavian artery, is usually gradual and accompanied by the development of an extensive web of collateral vessels  (<a class="graphic graphic_diagnosticimage graphicRef73553" href="/z/d/graphic/73553.html" rel="external">image 1</a>). With treatment of the underlying inflammatory process, the collateral circulation is commonly adequate to maintain the viability of distal tissues, even though there is some incident limb ischemia or diminished or absent peripheral arterial pulsations (brachial, radial, and ulnar). In 1 report of 53 treated patients with subclavian involvement due to GCA, symptoms and signs of ischemia resolved in 15 (27 percent), improved in 30 (55 percent), and were unchanged in 8 (15 percent) [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent2">If indicated, stenting or angioplasty should be undertaken when clinical evidence for inflammation has been suppressed with treatment. Restenosis is not infrequent [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Aortic aneurysms</strong> – Patients with aortic aneurysms related to GCA should be carefully evaluated for the presence of ongoing active vascular inflammation with laboratory (ESR, CRP) and imaging studies (magnetic resonance angiography [MRA], PET). Patients with active disease are treated with resumption or an increase in glucocorticoid therapy. If patients are not taking a glucocorticoid-sparing agent, this could be added. Additional information regarding medical and surgical management of thoracic aortic aneurysm and dissections is presented separately. (See  <a class="medical medical_review" href="/z/d/html/8189.html" rel="external">"Management of thoracic aortic aneurysm in adults"</a> and  <a class="medical medical_review" href="/z/d/html/8188.html" rel="external">"Management of acute type B aortic dissection"</a>.)</p><p></p><p class="headingAnchor" id="H446279165"><span class="h1">SUBSEQUENT MANAGEMENT</span></p><p class="headingAnchor" id="H1120030239"><span class="h2">Glucocorticoid tapering</span><span class="headingEndMark"> — </span>Symptoms and signs of giant cell arteritis (GCA) usually respond quickly to glucocorticoids, permitting a taper after two to four weeks. The approach to glucocorticoid tapering generally depends on whether patients are also receiving <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a>.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients on glucocorticoid monotherapy</strong> – For patients who are not on <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a>, we use a more standard, slower tapering regimen similar to that used in the Giant Cell Arteritis Actemra (GiACTA) trial  (<a class="graphic graphic_table graphicRef139301" href="/z/d/graphic/139301.html" rel="external">table 1</a>). The initial dose of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 60 mg/day can generally be reduced to 50 mg/day after two weeks and to 40 mg/day at the end of four weeks, assuming symptoms and signs have receded and the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) have declined to normal or near-normal ranges. Subsequently, the dose can gradually be reduced by 5 mg every two weeks to 20 mg/day and then by 2.5 mg every two weeks to 10 mg/day if there are no flares of disease activity. After achieving a daily dose of 10 mg, the prednisone taper should be slowed, such that patients remain on progressively decreasing doses over the ensuing 6 to 12 months. Tapering by 1 mg decrements each month once the daily dose is less than 10 mg can be considered, particularly in patients with concomitant polymyalgia rheumatica (PMR).</p><p></p><p class="bulletIndent1">In selected patients with significant risk for severe glucocorticoid toxicity and contraindications to <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> and <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, we use an accelerated taper regimen consistent with the taper used for patients on tocilizumab.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients on glucocorticoids plus </strong><strong>tocilizumab</strong> – For most patients with GCA receiving glucocorticoids in combination with <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a>, we use an accelerated glucocorticoid-tapering regimen. We use the accelerated tapering regimen used in the trial demonstrating the glucocorticoid-sparing effect of tocilizumab (GiACTA) [<a href="#rid19">19</a>]. Patients are initiated on <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 60 mg daily and tapered off over 26 weeks as indicated in the table  (<a class="graphic graphic_table graphicRef139298" href="/z/d/graphic/139298.html" rel="external">table 2</a>). The details of this study presented above. (See <a class="local">'Tocilizumab'</a> above.)</p><p></p><p class="headingAnchor" id="H32008885"><span class="h2">Routine monitoring of disease activity</span><span class="headingEndMark"> — </span>Monthly follow-up visits for the first six months of treatment are ideal, though their frequency will be subject to the exigencies of logistical issues. In stable patients, subsequent follow-up visits can be spaced out to every three months. Ultimately, all matters of follow-up (the interval between clinician visits, the frequency of laboratory monitoring, and the speed of the glucocorticoid taper) are governed by the clinical course of the given patient and must be individualized accordingly.</p><p>The goal of these visits is to evaluate the patient's response to therapy and assess for toxicity of the treatment regimen. Patients should be counseled to be watchful for symptoms of PMR or GCA and should be encouraged to seek medical attention immediately if any symptoms are noted.</p><p>The following data are obtained during follow-up visits:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>History and physical examination</strong> – At each visit, patients should routinely be asked about cranial symptoms (eg, headache, visual symptoms, jaw claudication) and PMR symptoms (eg, proximal musculoskeletal symptoms and/or signs), as well as any new or worsening symptoms and signs of large vessel involvement (eg, limb claudication, aortic murmur, peripheral loss of pulses).</p><p></p><p class="bulletIndent1">Patients should also be monitored for adverse effects from glucocorticoids (eg, osteoporosis, infection, diabetes, cataracts, and glaucoma) [<a href="#rid7">7</a>] and <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a>. (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a> and  <a class="medical medical_review" href="/z/d/html/129345.html" rel="external">"Interleukin 6 inhibitors: Biology, principles of use, and adverse effects", section on 'Adverse effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ESR and CRP</strong> – For patients who are not on <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a>, the ESR and CRP can be useful adjuncts to clinical decision making. Blockade of interleukin (IL) 6 activity with tocilizumab completely normalizes the ESR and CRP levels, with the result that these inflammatory makers are not useful for monitoring disease activity. Unfortunately, there are no useful alternative markers for monitoring disease activity in patients on tocilizumab, and clinicians must rely on clinical evaluation and, in the case of large vessel involvement, periodic imaging studies.</p><p></p><p class="bulletIndent1">For most patients on glucocorticoid monotherapy, the ESR and CRP usually improve substantially within a few days of the institution of therapy; the CRP declines much more rapidly than the ESR. Elevations of the ESR and CRP should be accompanied by other clinical findings suggestive of recrudescent GCA if changes in glucocorticoid doses are to be made. As markers of disease activity for large vessel GCA, the ESR and CRP have the same value and are accompanied by the same caveats as they do for the cranial phenotype.</p><p></p><p class="bulletIndent1">Both the ESR and CRP, however, are imperfect biomarkers in GCA. The ESR usually rises with age (a value of 40 mm/hour may be normal for an 80-year-old), and, in some patients, abnormalities of serum proteins unrelated to GCA can spuriously elevate the ESR. Examples include monoclonal gammopathies and hypergammaglobulinemia secondary to liver disease. Though the ESR and CRP have not been directly compared for the assessment of disease activity in GCA, clinical experience suggests that the CRP is more useful. (See  <a class="medical medical_review" href="/z/d/html/8225.html" rel="external">"Clinical manifestations of giant cell arteritis", section on 'Erythrocyte sedimentation rate and C-reactive protein'</a> and  <a class="medical medical_review" href="/z/d/html/7483.html" rel="external">"Acute phase reactants", section on 'Clinical use'</a>.)</p><p></p><p class="headingAnchor" id="H738140913"><span class="h2">Imaging surveillance for patients with large vessel involvement</span><span class="headingEndMark"> — </span>Different imaging modalities (CT, CT angiography [CTA], magnetic resonance imaging [MRI], MR angiography [MRA], and ultrasound) may be used for long-term monitoring of structural damage, particularly to detect stenosis, occlusion, dilatation, and/or aneurysms. The frequency of surveillance, as well as the imaging method applied, should be decided on an individual basis. Repeat imaging of a newly discovered or enlarging aortic aneurysm should be considered at six months of follow-up; if stable, the interval between imaging studies can be lengthened to an annual basis. The choice of an imaging modality will vary by institution and individual patient (see  <a class="medical medical_review" href="/z/d/html/8242.html" rel="external">"Diagnosis of giant cell arteritis", section on 'Imaging modalities'</a>). There are not enough data to recommend the routine use of any of the different imaging modalities for monitoring disease activity during follow-up of patients with large vessel GCA. As an example, in a large retrospective cohort study of patients diagnosed with large vessel GCA, positron emission tomography (PET)/CT grading showed moderate accuracy in distinguishing between clinically active and inactive disease, with a sensitivity of 51 and specificity of 83 percent [<a href="#rid41">41</a>]. Furthermore, PET/CT was not able to predict subsequent relapse. However, in selected cases in which a flare is suspected, imaging might be helpful to confirm or exclude it.</p><p class="headingAnchor" id="H1207756816"><span class="h2">Prevention of treatment-associated toxicity</span><span class="headingEndMark"> — </span>Immunosuppressive therapy with high-dose glucocorticoids with or without a glucocorticoid-sparing agent has both infectious and noninfectious toxicities that warrant additional prophylactic measures. The specific regimens are discussed in detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of opportunistic infections</strong> – Reports of <em>Pneumocystis jirovecii</em> pneumonia (PCP) in GCA are rare [<a href="#rid42">42,43</a>]. In a retrospective cohort study of 1168 patients with GCA, no cases of PCP were identified over 547 patient-years of follow-up [<a href="#rid44">44</a>]. However, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> use at 16 mg daily or more for eight weeks has been shown to be associated with an increased risk of PCP [<a href="#rid45">45</a>], and to date, the risk of PCP in patients on prednisone and <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> is unknown. While the absolute risk of PCP in GCA is small, some experts recommend PCP prophylaxis for patients with GCA given the risk of morbidity and mortality associated with PCP pneumonia. Ultimately, the decision to prescribe PCP prophylaxis should be individualized based on patient risk factors and preference and following a careful discussion of risks and benefit. (See  <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">"Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Indications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Osteoporosis prevention</strong> – Because of the length of the course of glucocorticoid treatment for GCA, osteoporosis prevention should be aggressively pursued at the start of therapy. Adequate dietary calcium and vitamin D intake should be encouraged. Determination of bone mineral density near the time that treatment is begun is essential for guiding management of bone loss. (See  <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age-appropriate vaccinations</strong> – Age-appropriate vaccinations should be up to date in immunosuppressed patients. (See  <a class="medical medical_review" href="/z/d/html/103773.html" rel="external">"Immunizations in autoimmune inflammatory rheumatic disease in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening for latent tuberculosis</strong> – Screening tests of latent tuberculosis should be performed at the start of therapy. (See  <a class="medical medical_review" href="/z/d/html/115049.html" rel="external">"Tuberculosis infection (latent tuberculosis) in adults: Approach to diagnosis (screening)"</a>.)</p><p></p><p class="headingAnchor" id="H3453723474"><span class="h1">DISEASE RELAPSE</span></p><p class="headingAnchor" id="H2552024958"><span class="h2">Incidence and clinical features</span><span class="headingEndMark"> — </span>Reports on the incidence of relapses in giant cell arteritis (GCA) vary widely, from 34 to 74 percent [<a href="#rid46">46-50</a>]. This range is due in part to a lack of consensus regarding the definition of what constitutes a relapse. In some analyses, asymptomatic rises in the acute phase reactants were counted as a flare of GCA and in others, a recrudescence of symptoms only, unaccompanied by rises in the acute phase reactants, was included. All studies construed the appearance of polymyalgia rheumatica (PMR) as a relapse of GCA.</p><p>Late relapses (and recurrences) of GCA are described, leading to protracted glucocorticoid treatment. In one study, one-half of patients were still on treatment after five years [<a href="#rid49">49</a>]. Other estimates of the total duration of glucocorticoid treatment are in the range of one to two years [<a href="#rid51">51,52</a>], which is more consonant with clinical practice.</p><p>The majority of relapses in GCA occur at doses of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> below 20 mg/day and are most prevalent during the first year of treatment. Headache and PMR are the most common symptomatic expressions of relapse. Other symptoms include jaw claudication, the development of ischemic limb symptoms, and the recurrence of constitutional symptoms. Elevations of the erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) do not always indicate a disease flare, but their occurrence should trigger close clinical follow-up and questioning of patients about symptoms of recurring disease. In addition, if elevations in ESR and CRP are accompanied by constitutional symptoms, diagnostic imaging for underlying large vessel vasculitis may be considered. The occurrence of sight loss after an initial course of high-dose glucocorticoid treatment, administered daily, is exceptional.</p><p class="headingAnchor" id="H3288908199"><span class="h2">Management</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Increase glucocorticoid dose</strong> – For patients who experience a relapse of GCA, we increase the glucocorticoid dose appropriate to the nature of the relapse. For visual symptoms attributable to GCA (generally occurring within the first weeks of the initial diagnosis of disease), an increase of the <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> dose to 40 to 60 mg/day and even pulse doses may be needed. For other symptoms, an increase of the daily dose of glucocorticoids to the last effective dose or 5 to 15 mg above this dose is appropriate. Smaller increments in the daily dose of prednisone, between 5 to 7.5 mg/day, are usually appropriate for PMR symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Addition of a glucocorticoid-sparing agent</strong> – For patients who are not already on a glucocorticoid-sparing agent at the time of relapse, a glucocorticoid-sparing agent, preferably <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a>, should be added. The rationale for this approach is based on data from the clinical trials of tocilizumab for GCA that included patients with relapsing disease. These trials are discussed in detail above. (See <a class="local">'Tocilizumab'</a> above.)</p><p></p><p class="bulletIndent1">For patients with relapsing disease while already on <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a>, in addition to increasing the glucocorticoid dose, some experts may modify the tocilizumab dose or route of administration when possible. This approach is based on clinical experience, as there are no data to support this approach. As an example, if a patient relapses while on tocilizumab subcutaneous injections every other week, the dosing frequency may be increased to weekly injections. As another example, if a patient relapses while receiving tocilizumab 6 mg/kg intravenously once every four weeks, they may have their dose increased to 8 mg/kg once every four weeks. Additionally, switching from subcutaneous administration to intravenous administration may be attempted.</p><p></p><p class="bulletIndent1">Entry into an investigational trial may also be an option at some institutions for patients with relapsing disease while already on <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a>.</p><p></p><p class="headingAnchor" id="H3643368432"><span class="h1">UNPROVEN OR INEFFECTIVE AGENTS</span><span class="headingEndMark"> — </span>Several other glucocorticoid-sparing agents have been reported as having efficacy as adjunctive treatment for giant cell arteritis (GCA), but their use cannot be endorsed because of small effect, potential toxicity, lack of controls, or small numbers of patients studied.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Abatacept</strong> – A trial of <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">abatacept</a>, a blocker of T-cell costimulation, was proposed on the basis of the presence of activated CD4+ T cells in the typical inflammatory infiltrate of the temporal artery in GCA [<a href="#rid53">53</a>] (see  <a class="medical medical_review" href="/z/d/html/8234.html" rel="external">"Pathogenesis of giant cell arteritis"</a>). In a phase 2 randomized, double-blind study of patients with newly diagnosed or relapsing GCA, 49 patients were enrolled and treated with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> and intravenous abatacept, administered on days 1, 15, 29, and 56. At week 12, 41 patients were in remission and were randomized to continue treatment with monthly abatacept or placebo. Prednisone was tapered by a standardized schedule and discontinued by week 28. The rate of sustained remission at 12 months in patients treated with abatacept compared with placebo was of borderline statistical significance, 48 versus 31 percent. There was no difference in adverse events, including infection, between the two groups.</p><p></p><p class="bulletIndent1">Further study is needed to determine a possible role for <a class="drug drug_general" data-topicid="8526" href="/z/d/drug information/8526.html" rel="external">abatacept</a> as adjunctive treatment for GCA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="99569" href="/z/d/drug information/99569.html" rel="external">Secukinumab</a> – In a randomized trial of 52 patients with either newly diagnosed or relapsing GCA, subcutaneous secukinumab (300 mg weekly for the first four weeks, and every four weeks thereafter) improved the rate of sustained remission through 28 weeks compared with placebo (70 versus 20 percent) when each was given in addition to a 26-week glucocorticoid taper [<a href="#rid54">54</a>]. There was no difference in adverse events between the two groups. One patient died in each arm of the study; neither death was attributed to the study treatment. Further study is needed to determine a possible role for secukinumab as adjunctive treatment for GCA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Baricitinib</strong> – Preclinical findings and case reports have demonstrated the biologic plausibility that agents selectively targeting Janus kinase (JAK) 1/JAK2 hold potential promise in GCA. In a prospective, open-label, proof-of-concept study with a tiered glucocorticoid entry and accelerated taper in patients with relapsing GCA, the oral selective JAK1/JAK2 inhibitor <a class="drug drug_general" data-topicid="118052" href="/z/d/drug information/118052.html" rel="external">baricitinib</a> at 4 mg/day was well tolerated and allowed discontinuation of glucocorticoids in most patients [<a href="#rid55">55</a>]. Larger randomized clinical trials are needed to determine the safety and efficacy of JAK inhibition in GCA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mavrilimumab</strong> – Preclinical research has implicated granulocyte-macrophage colony-stimulating factor (GM-CSF) in the pathogenesis of GCA. Mavrilimumab, an immunoglobulin (Ig) G4 monoclonal antibody, blocks GM-CSF signaling by binding to the alpha chain of the receptor. In a phase 2 trial enrolling patients with GCA, mavrilimumab plus 26 weeks of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> was superior to placebo for time to flare by week 26 and sustained remission [<a href="#rid56">56</a>]. Further studies are needed to define the potential role of mavrilimumab in the treatment of GCA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">Tocilizumab</a> – Three proof-of-concept studies evaluated the efficacy and safety of tocilizumab monotherapy after ultra-short-term glucocorticoid treatment: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the first study, 18 patients with newly diagnosed GCA received 500 mg <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> intravenously for three consecutive days. Thereafter, glucocorticoid treatment was discontinued, and a single infusion of <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> (8 mg/kg bodyweight) was administered intravenously, followed by weekly subcutaneous tocilizumab injections (162 mg) until week 52 [<a href="#rid57">57</a>]. Only 22 percent of patients achieved remission within 31 days and had no relapse at week 24 (primary endpoint). However, 78 percent of the enrolled patients achieved remission within 24 weeks, and 72 percent remained relapse-free until 52 weeks. One patient developed unilateral arteritic anterior ischemic optic neuropathy 15 days after the third glucocorticoid infusion.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the second study, 18 patients with newly diagnosed or relapsing active large vessel GCA received 500 mg <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a> intravenously for three consecutive days followed by weekly subcutaneous <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> injections (162 mg) from day 4 until week 52 [<a href="#rid58">58</a>]. The proportion of patients with relapse-free remission at weeks 24 and 52 was 56 and 47 percent, respectively. Compared with baseline, there was a significant reduction of vascular inflammation evaluated by PET/CT at weeks 24 and 52. No patient showed new aortic dilation. However, four patients who had shown aortic dilation at baseline showed a significant increase in aortic diameter (≥5 mm) at week 52.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the third study, 30 patients with newly diagnosed or relapsing GCA were treated with 52 weeks of subcutaneous <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> (162 mg weekly) and an eight-week <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> taper (starting with 60 mg daily) [<a href="#rid59">59</a>]. All patients entered remission after four weeks of therapy; 77 percent of patients remained in a glucocorticoid-free remission by week 52. Among the patients who relapsed, the mean time to relapse was 16 weeks.</p><p></p><p class="bulletIndent1">As proof-of-concept studies, these data are insufficient to guide changes in current clinical practice. An ultra-short course of glucocorticoids in combination with <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> may be an option for a subset of patients with GCA; however, randomized controlled trials and longer-term longitudinal studies will be necessary to fully understand the efficacy and safety of this treatment regimen.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Azathioprine</strong> – In a study from a single center of 31 patients with GCA, polymyalgia rheumatica (PMR), or both, a double-blind randomized controlled study of <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, 150 mg/day, versus placebo showed a small but statistically significant reduction in mean <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> dose at 52 weeks (1.9 mg/day±0.84 versus 4.2 mg/day±0.58) [<a href="#rid60">60</a>]. Only 20 patients completed the study.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ustekinumab</strong> – T helper (Th) 1 and Th17 cells are believed to play key roles in the pathogenesis of GCA [<a href="#rid61">61</a>] (see  <a class="medical medical_review" href="/z/d/html/8234.html" rel="external">"Pathogenesis of giant cell arteritis"</a>). <a class="drug drug_general" data-topicid="9514" href="/z/d/drug information/9514.html" rel="external">Ustekinumab</a> blocks interleukin (IL) 12, a Th1-promoting cytokine, and IL-23, a Th17-promoting cytokine, providing a theoretical basis for its use in the treatment of GCA. In an open-label study of ustekinumab in 14 patients with refractory GCA, the <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> dose was decreased from a median of 20 mg/day to 5 mg/day; four patients discontinued glucocorticoid therapy entirely [<a href="#rid62">62</a>]. However, a subsequent prospective, open-label trial of ustekinumab in patients with active new-onset or relapsing GCA was closed prematurely after 7 of the initial 10 patients relapsed [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cyclophosphamide</strong> – <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">Cyclophosphamide</a> has been widely used in the treatment of systemic vasculitis. A few small, uncontrolled studies have suggested that it may be useful in GCA in patients at high risk of glucocorticoid-related adverse effects who have not responded adequately to other immunosuppressive or immunomodulatory glucocorticoid-sparing treatments [<a href="#rid64">64-66</a>]. A systematic review identified 103 published cases for analysis [<a href="#rid66">66</a>]. The major indications for cyclophosphamide, administered either orally or intravenously, included glucocorticoid dependency or relapsing disease. Most of the reported patients (86 percent) responded, but 22 percent relapsed despite maintenance immunosuppressive therapy. Adverse effects were described in one-third of the patients, and 12.5 percent discontinued the therapy because of infections and cytopenias. One death due to hepatitis was reported.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Others</strong> – Small, uncontrolled, retrospective series have proposed benefit for <a class="drug drug_general" data-topicid="9324" href="/z/d/drug information/9324.html" rel="external">dapsone</a> [<a href="#rid67">67</a>], <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a> [<a href="#rid68">68</a>], and IL-1 blockade [<a href="#rid69">69</a>] for the management of GCA.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lack of benefit of anti-TNF therapy</strong> – Because GCA is characterized by granulomatous inflammation, tumor necrosis factor (TNF) inhibition would appear to be an appropriate approach to treatment. However, several small randomized trials of TNF inhibition have found that <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a>, and <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a> are ineffective in patients with GCA [<a href="#rid70">70-72</a>]. As an example, 44 patients were studied in a multicenter, randomized, placebo-controlled trial of infliximab for the maintenance of remission [<a href="#rid70">70</a>]. After prednisone-induced remission, patients were randomly assigned in a 2:1 ratio to infliximab 5 mg/kg or placebo. An interim analysis at week 22 demonstrated that infliximab did not reduce the proportion of patients with relapses (43 versus 50 percent on placebo). In addition, infliximab did not increase the proportion of patients whose <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> dose could be tapered to 10 mg/day without relapse (61 versus 75 percent). Consequently, the trial was stopped early. Through the follow-up period, no differences between the treatment groups were observed in the proportion of relapse-free patients, the cumulative dose of prednisone, or the incidence of adverse events.</p><p></p><p class="headingAnchor" id="H19"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Giant cell arteritis (GCA) is a disease of variable duration. In some, it may have a course of one to two years, while in many others, the disease is more chronic. The glucocorticoid dose can eventually be reduced and discontinued in the majority of patients, although some patients require low doses of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> for a number of years to control symptoms.</p><p>GCA does not adversely affect overall survival, excepting the subset of patients with aortic involvement and dissection [<a href="#rid73">73-75</a>].</p><p class="headingAnchor" id="H3236024603"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117108.html" rel="external">"Society guideline links: Giant cell arteritis and polymyalgia rheumatica"</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/15532.html" rel="external">"Patient education: Polymyalgia rheumatica and giant cell arteritis (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/579.html" rel="external">"Patient education: Vasculitis (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/576.html" rel="external">"Patient education: Polymyalgia rheumatica and giant cell arteritis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H736599572"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Systemic glucocorticoids</strong> – For all patients with giant cell arteritis (GCA), we recommend initial treatment with high-dose systemic glucocorticoids to preserve vision (<a class="grade" href="https:///uptodate/show/grade_3" rel="external">Grade 1C</a>), as well as to treat other clinical symptoms associated with GCA (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Treatment should be initiated promptly once the diagnosis is confirmed or there is a high index of suspicion for GCA. Our practice regarding the specific dose and route of administration of glucocorticoids for newly diagnosed GCA is as follows (see <a class="local">'Glucocorticoids'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>No visual loss at diagnosis</strong> – <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">Prednisone</a> 40 to 60 mg/day or equivalent, given in a single daily dose.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Threatened or established visual loss at diagnosis</strong> – <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">Methylprednisolone</a> 500 to 1000 mg intravenous daily, for three days (followed by 40 to 60 mg/day of oral <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Glucocorticoid-sparing agent in selected patients</strong> – For patients with newly diagnosed GCA with an increased risk of glucocorticoid-related adverse effects, we suggest the addition of <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> to glucocorticoid therapy (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Patients who are at increased risk of developing glucocorticoid-related side effects or complications include those with osteoporosis, diabetes, cardiovascular disease, or glaucoma. Tocilizumab has demonstrated a glucocorticoid-sparing effect in clinical trials. (See <a class="local">'Glucocorticoid-sparing agent in selected patients'</a> above and <a class="local">'Indications and rationale'</a> above and <a class="local">'Tocilizumab'</a> above.)</p><p></p><p class="bulletIndent2">Whether a glucocorticoid-sparing agent should be used in the routine care of all patients with GCA is uncertain. The American College of Rheumatology (ACR) recommends the use of adjunctive <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> for all patients with GCA.</p><p></p><p class="bulletIndent2"><a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">Methotrexate</a> may be used as an alternative to <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> for patients who are unable to use the medication due to factors such as availability, cost, recurrent infections, or a history of gastrointestinal perforations or diverticulitis; however, limited available data and clinical experience suggest methotrexate is less effective. (See <a class="local">'Methotrexate'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with large vessel involvement</strong> – Patients with large vessel GCA are managed in a manner similar to those without large vessel involvement. Additional considerations include antiplatelet therapy in selected patients as well as possible surgical interventions for patients with vascular complications. (See <a class="local">'Patients with large vessel involvement'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Glucocorticoid tapering</strong> – Symptoms and signs of GCA usually respond quickly to glucocorticoids, permitting the initiation of a taper after one to two weeks. The approach to glucocorticoid tapering varies generally depends on whether patients are also receiving <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a>. (See <a class="local">'Glucocorticoid tapering'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Patients on glucocorticoid monotherapy</strong> – For patients with GCA receiving monotherapy with glucocorticoids, we use a standard glucocorticoid tapering regimen  (<a class="graphic graphic_table graphicRef139301" href="/z/d/graphic/139301.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Patients on glucocorticoids plus </strong><strong>tocilizumab</strong> – For most patients with GCA receiving glucocorticoids in combination with <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> (or another glucocorticoid-sparing agent), we use an accelerated glucocorticoid-tapering regimen  (<a class="graphic graphic_table graphicRef139298" href="/z/d/graphic/139298.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Routine monitoring of disease activity</strong> – Monitoring of disease activity requires careful clinical follow-up to evaluate the patient's response to therapy and assess for toxicity of the treatment regimen. For patients who are not on <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a>, the erythrocyte sedimentation rate (ESR) and the C-reactive protein (CRP) can be useful adjuncts to clinical decision making. Tocilizumab completely normalizes the ESR and CRP levels, and they are thus not useful for monitoring disease activity in such patients. Clinicians must rely on clinical evaluation and, in the case of large vessel involvement, periodic imaging studies for patients on tocilizumab. (See <a class="local">'Routine monitoring of disease activity'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Imaging surveillance for patients with large vessel involvement</strong> – Different imaging modalities (CT, CT angiography [CTA], MRI, MR angiography [MRA], and ultrasound) may be used for long-term monitoring of structural damage, particularly to detect stenosis, occlusion, dilatation, and/or aneurysms. The frequency of surveillance, as well as the imaging method applied, should be decided on an individual basis. (See <a class="local">'Imaging surveillance for patients with large vessel involvement'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prevention of treatment-associated toxicity</strong> – Immunosuppressive therapy with high-dose glucocorticoids with or without a glucocorticoid-sparing agent has both infectious and noninfectious toxicities that warrant additional prophylactic measures including prevention of opportunistic infections, osteoporosis prevention, age-appropriate vaccinations, and screening for latent tuberculosis. (See <a class="local">'Prevention of treatment-associated toxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease relapse</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Incidence and clinical features</strong> – Relapses of disease activity are most common at <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> doses less than 20 mg/day and are most prevalent during the first year of treatment. Headache and polymyalgia rheumatica (PMR) are the most common symptomatic expressions of relapse. Relapses usually do not result in major adverse events such as visual loss. (See <a class="local">'Incidence and clinical features'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management of relapse</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients who experience a relapse of GCA, we increase the glucocorticoid dose appropriate to the nature of the relapse.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients who are not already on a glucocorticoid-sparing agent at the time of relapse, we suggest adding <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">tocilizumab</a> (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – GCA is a disease of variable duration. Length of treatment may extend from one to multiple years. Glucocorticoid treatment can eventually be discontinued in the majority of patients. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="headingAnchor" id="H1582560035"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Gene G Hunder, MD and William P Docken, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum 2011; 63:633.</a></li><li><a class="nounderline abstract_t">González-Gay MA, García-Porrúa C. Systemic vasculitis in adults in northwestern Spain, 1988-1997. Clinical and epidemiologic aspects. Medicine (Baltimore) 1999; 78:292.</a></li><li><a class="nounderline abstract_t">Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009; 61:1454.</a></li><li><a class="nounderline abstract_t">BIRKHEAD NC, WAGENER HP, SHICK RM. Treatment of temporal arteritis with adrenal corticosteroids; results in fifty-five cases in which lesion was proved at biopsy. J Am Med Assoc 1957; 163:821.</a></li><li><a class="nounderline abstract_t">Aiello PD, Trautmann JC, McPhee TJ, et al. Visual prognosis in giant cell arteritis. Ophthalmology 1993; 100:550.</a></li><li><a class="nounderline abstract_t">Hayreh SS, Zimmerman B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology 2003; 110:1204.</a></li><li><a class="nounderline abstract_t">Proven A, Gabriel SE, Orces C, et al. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003; 49:703.</a></li><li><a class="nounderline abstract_t">Delecoeuillerie G, Joly P, Cohen de Lara A, Paolaggi JB. Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients). Ann Rheum Dis 1988; 47:733.</a></li><li><a class="nounderline abstract_t">Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects. Ann Rheum Dis 1989; 48:662.</a></li><li><a class="nounderline abstract_t">Hayreh SS, Zimmerman B. Management of giant cell arteritis. Our 27-year clinical study: new light on old controversies. Ophthalmologica 2003; 217:239.</a></li><li><a class="nounderline abstract_t">Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2020; 79:19.</a></li><li><a class="nounderline abstract_t">Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Care Res (Hoboken) 2021; 73:1071.</a></li><li><a class="nounderline abstract_t">Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Rheumatol 2021; 73:1349.</a></li><li><a class="nounderline abstract_t">Chevalet P, Barrier JH, Pottier P, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol 2000; 27:1484.</a></li><li><a class="nounderline abstract_t">Hayreh SS, Biousse V. Treatment of acute visual loss in giant cell arteritis: should we prescribe high-dose intravenous steroids or just oral steroids? J Neuroophthalmol 2012; 32:278.</a></li><li><a class="nounderline abstract_t">Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002; 46:1309.</a></li><li><a class="nounderline abstract_t">Hunder GG, Sheps SG, Allen GL, Joyce JW. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann Intern Med 1975; 82:613.</a></li><li><a class="nounderline abstract_t">Villiger PM, Adler S, Kuchen S, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: A phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2016; 387:1921.</a></li><li><a class="nounderline abstract_t">Stone JH, Tuckwell K, Dimonaco S, et al. Trial of Tocilizumab in Giant-Cell Arteritis. N Engl J Med 2017; 377:317.</a></li><li><a class="nounderline abstract_t">Stone JH, Han J, Aringer M, et al. Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial. Lancet Rheumatol 2021; 3:e328.</a></li><li><a class="nounderline abstract_t">Unizony S, Arias-Urdaneta L, Miloslavsky E, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken) 2012; 64:1720.</a></li><li><a class="nounderline abstract_t">Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review. JAMA 2016; 315:2442.</a></li><li><a class="nounderline abstract_t">Jover JA, Hernández-García C, Morado IC, et al. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 134:106.</a></li><li><a class="nounderline abstract_t">Spiera RF, Mitnick HJ, Kupersmith M, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 2001; 19:495.</a></li><li><a class="nounderline abstract_t">Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007; 56:2789.</a></li><li><a class="nounderline abstract_t">Schönau V, Roth J, Tascilar K, et al. Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study. Rheumatology (Oxford) 2021; 60:3851.</a></li><li><a class="nounderline abstract_t">Castillejo Becerra CM, Crowson CS, Koster MJ, et al. Population-based Rate and Patterns of Diplopia in Giant Cell Arteritis. Neuroophthalmology 2022; 46:75.</a></li><li><a class="nounderline abstract_t">Hayreh SS, Zimmerman B, Kardon RH. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand 2002; 80:355.</a></li><li><a class="nounderline abstract_t">Danesh-Meyer H, Savino PJ, Gamble GG. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology 2005; 112:1098.</a></li><li><a class="nounderline abstract_t">Singh AG, Kermani TA, Crowson CS, et al. Visual manifestations in giant cell arteritis: trend over 5 decades in a population-based cohort. J Rheumatol 2015; 42:309.</a></li><li><a class="nounderline abstract_t">Soriano A, Muratore F, Pipitone N, et al. Visual loss and other cranial ischaemic complications in giant cell arteritis. Nat Rev Rheumatol 2017; 13:476.</a></li><li><a class="nounderline abstract_t">González-Gay MA, Blanco R, Rodríguez-Valverde V, et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 1998; 41:1497.</a></li><li><a class="nounderline abstract_t">Hayreh SS, Podhajsky PA, Zimmerman B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol 1998; 125:509.</a></li><li><a class="nounderline abstract_t">Muratore F, Kermani TA, Crowson CS, et al. Large-vessel giant cell arteritis: a cohort study. Rheumatology (Oxford) 2015; 54:463.</a></li><li><a class="nounderline abstract_t">Nesher G, Berkun Y, Mates M, et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004; 50:1332.</a></li><li><a class="nounderline abstract_t">Lee MS, Smith SD, Galor A, Hoffman GS. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 2006; 54:3306.</a></li><li><a class="nounderline abstract_t">Narváez J, Bernad B, Gómez-Vaquero C, et al. Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin Exp Rheumatol 2008; 26:S57.</a></li><li><a class="nounderline abstract_t">Salvarani C, Della Bella C, Cimino L, et al. Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology (Oxford) 2009; 48:250.</a></li><li><a class="nounderline abstract_t">Berger CT, Wolbers M, Meyer P, et al. High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition. Rheumatology (Oxford) 2009; 48:258.</a></li><li><a class="nounderline abstract_t">Amann-Vesti BR, Koppensteiner R, Rainoni L, et al. Immediate and long-term outcome of upper extremity balloon angioplasty in giant cell arteritis. J Endovasc Ther 2003; 10:371.</a></li><li><a class="nounderline abstract_t">Galli E, Muratore F, Mancuso P, et al. The role of PET/CT in disease activity assessment in patients with large vessel vasculitis. Rheumatology (Oxford) 2022; 61:4809.</a></li><li><a class="nounderline abstract_t">Kermani TA, Ytterberg SR, Warrington KJ. Pneumocystis jiroveci pneumonia in giant cell arteritis: A case series. Arthritis Care Res (Hoboken) 2011; 63:761.</a></li><li><a class="nounderline abstract_t">Berger CT, Greiff V, John S, et al. Risk factors for pneumocystis pneumonia in giant cell arteritis: a single-centre cohort study. Clin Exp Rheumatol 2015; 33:S.</a></li><li><a class="nounderline abstract_t">Anumolu N, Henry K, Sattui SE, Putman M. Is there a role for Pneumocystis jiroveci pneumonia prophylaxis in giant cell arteritis or polymyalgia rheumatica? Semin Arthritis Rheum 2023; 58:152154.</a></li><li><a class="nounderline abstract_t">Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996; 71:5.</a></li><li><a class="nounderline abstract_t">Kermani TA, Warrington KJ, Cuthbertson D, et al. Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study. J Rheumatol 2015; 42:1213.</a></li><li><a class="nounderline abstract_t">Martinez-Lado L, Calviño-Díaz C, Piñeiro A, et al. Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine (Baltimore) 2011; 90:186.</a></li><li><a class="nounderline abstract_t">Alba MA, García-Martínez A, Prieto-González S, et al. Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Medicine (Baltimore) 2014; 93:194.</a></li><li><a class="nounderline abstract_t">Labarca C, Koster MJ, Crowson CS, et al. Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study. Rheumatology (Oxford) 2016; 55:347.</a></li><li><a class="nounderline abstract_t">Restuccia G, Boiardi L, Cavazza A, et al. Flares in Biopsy-Proven Giant Cell Arteritis in Northern Italy: Characteristics and Predictors in a Long-Term Follow-Up Study. Medicine (Baltimore) 2016; 95:e3524.</a></li><li><a class="nounderline abstract_t">Hoffman GS. Giant Cell Arteritis. Ann Intern Med 2016; 165:ITC65.</a></li><li><a class="nounderline abstract_t">Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008; 372:234.</a></li><li><a class="nounderline abstract_t">Langford CA, Cuthbertson D, Ytterberg SR, et al. A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. Arthritis Rheumatol 2017; 69:837.</a></li><li><a class="nounderline abstract_t">Venhoff N, Schmidt WA, Bergner R, et al. Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Rheumatol 2023; 5:e341.</a></li><li><a class="nounderline abstract_t">Koster MJ, Crowson CS, Giblon RE, et al. Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study. Ann Rheum Dis 2022; 81:861.</a></li><li><a class="nounderline abstract_t">Cid MC, Unizony SH, Blockmans D, et al. Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2022; 81:653.</a></li><li><a class="nounderline abstract_t">Christ L, Seitz L, Scholz G, et al. Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: a single-arm, open-label, proof-of-concept study. Lancet Rheumatol 2021; 3:e619.</a></li><li><a class="nounderline abstract_t">Muratore F, Marvisi C, Cassone G, et al. Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: the role of imaging in a prospective observational study. Rheumatology (Oxford) 2024; 63:64.</a></li><li><a class="nounderline abstract_t">Unizony S, Matza MA, Jarvie A, et al. Treatment for giant cell arteritis with 8 weeks of prednisone in combination with tocilizumab: a single-arm, open-label, proof-of-concept study. Lancet Rheumatol 2023; 5:e736.</a></li><li><a class="nounderline abstract_t">De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986; 45:136.</a></li><li><a class="nounderline abstract_t">Deng J, Younge BR, Olshen RA, et al. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 2010; 121:906.</a></li><li><a class="nounderline abstract_t">Conway R, O'Neill L, O'Flynn E, et al. Ustekinumab for the treatment of refractory giant cell arteritis. Ann Rheum Dis 2016; 75:1578.</a></li><li><a class="nounderline abstract_t">Matza MA, Fernandes AD, Stone JH, Unizony SH. Ustekinumab for the Treatment of Giant Cell Arteritis. Arthritis Care Res (Hoboken) 2021; 73:893.</a></li><li><a class="nounderline abstract_t">Quartuccio L, Maset M, De Maglio G, et al. Role of oral cyclophosphamide in the treatment of giant cell arteritis. Rheumatology (Oxford) 2012; 51:1677.</a></li><li><a class="nounderline abstract_t">Henes JC, Mueller M, Pfannenberg C, et al. Cyclophosphamide for large vessel vasculitis: assessment of response by PET/CT. Clin Exp Rheumatol 2011; 29:S43.</a></li><li><a class="nounderline abstract_t">de Boysson H, Boutemy J, Creveuil C, et al. Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review. Semin Arthritis Rheum 2013; 43:105.</a></li><li><a class="nounderline abstract_t">Ly KH, Dalmay F, Gondran G, et al. Steroid-sparing effect and toxicity of dapsone treatment in giant cell arteritis: A single-center, retrospective study of 70 patients. Medicine (Baltimore) 2016; 95:e4974.</a></li><li><a class="nounderline abstract_t">Diamantopoulos AP, Hetland H, Myklebust G. Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series. Biomed Res Int 2013; 2013:120638.</a></li><li><a class="nounderline abstract_t">Ly KH, Stirnemann J, Liozon E, et al. Interleukin-1 blockade in refractory giant cell arteritis. Joint Bone Spine 2014; 81:76.</a></li><li><a class="nounderline abstract_t">Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007; 146:621.</a></li><li><a class="nounderline abstract_t">Seror R, Baron G, Hachulla E, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis 2014; 73:2074.</a></li><li><a class="nounderline abstract_t">Martínez-Taboada VM, Rodríguez-Valverde V, Carreño L, et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008; 67:625.</a></li><li><a class="nounderline abstract_t">Kermani TA, Warrington KJ, Crowson CS, et al. Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis. Ann Rheum Dis 2013; 72:1989.</a></li><li><a class="nounderline abstract_t">González-Gay MA, Blanco R, Abraira V, et al. Giant cell arteritis in Lugo, Spain, is associated with low longterm mortality. J Rheumatol 1997; 24:2171.</a></li><li><a class="nounderline abstract_t">Gran JT, Myklebust G, Wilsgaard T, Jacobsen BK. Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls. Rheumatology (Oxford) 2001; 40:1238.</a></li></ol></div><div id="topicVersionRevision">Topic 8240 Version 42.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21360492" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10499071" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Systemic vasculitis in adults in northwestern Spain, 1988-1997. Clinical and epidemiologic aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19790127" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Epidemiology of giant cell arteritis and polymyalgia rheumatica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13405740" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Treatment of temporal arteritis with adrenal corticosteroids; results in fifty-five cases in which lesion was proved at biopsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8479714" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Visual prognosis in giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12799248" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14558057" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3178314" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2782976" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Treatment of polymyalgia rheumatica and giant cell arteritis. II. Relation between steroid dose and steroid associated side effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12792130" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Management of giant cell arteritis. Our 27-year clinical study: new light on old controversies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31270110" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : 2018 Update of the EULAR recommendations for the management of large vessel vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34235871" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34235884" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10852275" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22914694" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Treatment of acute visual loss in giant cell arteritis: should we prescribe high-dose intravenous steroids or just oral steroids?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12115238" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1137255" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26952547" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Tocilizumab for induction and maintenance of remission in giant cell arteritis: A phase 2, randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28745999" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Trial of Tocilizumab in Giant-Cell Arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38279390" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22674883" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27299619" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11177313" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11579707" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17665429" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33831144" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35273408" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Population-based Rate and Patterns of Diplopia in Giant Cell Arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12190776" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15885780" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Poor prognosis of visual outcome after visual loss from giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25512481" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Visual manifestations in giant cell arteritis: trend over 5 decades in a population-based cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28680132" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Visual loss and other cranial ischaemic complications in giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9704651" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9559737" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Ocular manifestations of giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25193809" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Large-vessel giant cell arteritis: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15077317" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17009265" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Antiplatelet and anticoagulant therapy in patients with giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18799055" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19109317" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19129348" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12877626" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Immediate and long-term outcome of upper extremity balloon angioplasty in giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35258570" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The role of PET/CT in disease activity assessment in patients with large vessel vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21240966" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pneumocystis jiroveci pneumonia in giant cell arteritis: A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26016762" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Risk factors for pneumocystis pneumonia in giant cell arteritis: a single-centre cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36563422" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Is there a role for Pneumocystis jiroveci pneumonia prophylaxis in giant cell arteritis or polymyalgia rheumatica?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8538233" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25877501" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21512412" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25181312" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Relapses in patients with giant cell arteritis: prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26385368" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Predictors of relapse and treatment outcomes in biopsy-proven giant cell arteritis: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27175649" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Flares in Biopsy-Proven Giant Cell Arteritis in Northern Italy: Characteristics and Predictors in a Long-Term Follow-Up Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27802475" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Giant Cell Arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18640460" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Polymyalgia rheumatica and giant-cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28133925" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38251601" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Safety and efficacy of secukinumab in patients with giant cell arteritis (TitAIN): a randomised, double-blind, placebo-controlled, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35190385" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Baricitinib for relapsing giant cell arteritis: a prospective open-label 52-week pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35264321" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38287611" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Tocilizumab monotherapy after ultra-short glucocorticoid administration in giant cell arteritis: a single-arm, open-label, proof-of-concept study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37195423" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: the role of imaging in a prospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38251564" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Treatment for giant cell arteritis with 8 weeks of prednisone in combination with tocilizumab: a single-arm, open-label, proof-of-concept study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3511861" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20142449" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Th17 and Th1 T-cell responses in giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27143653" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Ustekinumab for the treatment of refractory giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32248659" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Ustekinumab for the Treatment of Giant Cell Arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22627726" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Role of oral cyclophosphamide in the treatment of giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21385544" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Cyclophosphamide for large vessel vasculitis: assessment of response by PET/CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23453684" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27759628" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Steroid-sparing effect and toxicity of dapsone treatment in giant cell arteritis: A single-center, retrospective study of 70 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24106691" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23890680" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Interleukin-1 blockade in refractory giant cell arteritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17470830" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23897775" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18086726" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23253927" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9375880" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Giant cell arteritis in Lugo, Spain, is associated with low longterm mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11709607" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Survival in polymyalgia rheumatica and temporal arteritis: a study of 398 cases and matched population controls.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
